Oslo

• PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma Recruiting
  2022-501993-21-00 4 2024-06-20 Dedifferentiated Liposarcoma
• MethMax trial Recruiting
  2023-507714-27-00 6 2024-06-20 Rheumatoid Arthritis
• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants … Recruiting
  2022-501697-19-01 5 2024-06-18 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
• A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared … Recruiting
  2023-508156-20-00 5 2024-06-10 Uveal Melanoma Liver Metastases
• Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys? Recruiting
  2023-510485-27-00 6 2024-06-06 Kidney transplantation
• Phase 2, randomised study of Radspherin® in patients with primary advanced epithelial cancer with peritoneal metastasis that are homologous … Recruiting
  2023-508497-28-00 4 2024-06-05 Carcinomatosis of peritoneal cavity
• A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting
  2023-506150-21-00 4 2024-05-29 Celiac Disease
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un … Recruiting
  2023-508613-17-00 5 2024-05-29 Neoplasms, Head and Neck
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma
• COMBINATORY IMMUNOTHERAPY-2 (COM-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy comb … Recruiting
  2023-510089-28-00 9 2024-05-22 Non-small cell lung cancer (Stage IV)
• Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects Recruiting
  2023-510486-10-00 6 2024-05-22 Kidney transplantation
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• Antibiotic THErapy iN vIral Airway iNfections (ATHENIAN): An open labelled randomized controlled pragmatic trial to evaluate the efficacy an … Recruiting
  2023-509286-20-00 6 2024-05-15 Viral respiratory tract infection
• Atorvastatin in episodic migraine Recruiting
  2022-502176-23-01 4 2024-05-13 Migraine
• Atorvastatin in chronic migraine (StainMigChronic) Recruiting
  2022-502177-42-02 4 2024-05-13 Chronic migraine
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• A Study to Investigate the Pharmacokinetics (PK) and Safety of Risdiplam in Infants with Spinal Muscular Atrophy Recruiting
  2023-505602-42-00 4 2024-04-30 Spinal Muscular Atrophy (SMA)
• A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting
  2023-504374-38-00 5 2024-04-12 Locally advanced cervical cancer
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• ​​Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma Recruiting
  2023-505267-36-00 5 2024-03-15 Glioblastoma
• Chiropractic spinal manipulative therapy for acute neck pain: a 4-armed clinical placebo randomized controlled trial Recruiting
  2023-509624-17-00 6 2024-03-08 Acute neck pain
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-504735-41-00 5 2024-03-05 Moderately to Severely Active Crohn's Disease
• OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Stud … Recruiting
  2022-501408-81-01 4 2024-03-04 Covid-19
• Preeclampsia Intervention 4 Recruiting
  2022-502707-29-00 5 2024-02-07 Preeclampsia

Showing 193–216 of 508 trials